Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 22, 2018 08:00 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., March 22, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and...
March 01, 2018 08:00 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics to Present at March Investor Conferences

CAMBRIDGE, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
February 01, 2018 08:00 ET | Source: Spero Therapeutics, Inc.

Spero Announces Appointment of David P. Southwell to its Board of Directors

CAMBRIDGE, Mass., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
January 04, 2018 07:30 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Appoints David Melnick, M.D., as Chief Medical Officer

CAMBRIDGE, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
December 14, 2017 16:15 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces 3Q17 Operating Results and Pipeline Update

Raised approximately $83.6 million in gross proceeds from Initial Public OfferingAdvanced pipeline with initiation of SPR994 Phase 1 trial in October 2017 and SPR741 Phase 1b trial in November 2017 ...
November 13, 2017 07:00 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces Underwriters’ Option Exercise

CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and...
November 06, 2017 16:01 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces Closing of Initial Public Offering

CAMBRIDGE, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel...
November 01, 2017 18:00 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel...
October 23, 2017 07:00 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Launches Initial Public Offering

CAMBRIDGE, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel...
October 20, 2017 08:00 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Initiates Clinical Program for Oral Carbapenem SPR994

Clinical study to evaluate potential first ever orally administered carbapenem being developed for multi-drug resistant (MDR) Gram-negative infectionsInitiation of pivotal Phase 3 clinical trial in...